Tool 16: [Checklist: Specify the content of Treatment or Diagnostics collaboration](#Tool11_15)

The questions and topics in this checklist are designed to help the project partners set up a cross-border collaboration project in the field of *Treatment and Diagnostics* and to draw their attention to specific issues related to the scope of the collaboration, stakeholders and project partners, the target group, organisational and legal issues, and financing.


Please go through the list and put a cross in the relevant field (‘yes’, ‘no’) if you have considered the criteria. Comments (e.g. reasons for non-consideration) can be entered separately.

| Topic | Criteria | To be considered | | Comments |
| --- | --- | --- | --- | --- |
| Yes | No |
| Scope | What is the rationale behind the cross-border collaboration in treatment and diagnostics?   * Low volume of complex procedures * Geographical proximity * Access or waiting times |  |  |  |
| Is there **evidence of the health problem** and its impact on quality of life?   * How do we know about the problem? * Are empirical data available about the nature, size and distribution of the problem? * Is evidence of the factors that impact the health problem available? |  |  |  |
| * How will we address these factors? What means of treatment or diagnostic services should be provided to the target population? |  |  |  |
| Are we **familiar** with **other (similar) projects** and their success in addressing this issue? What can we learn and apply? |  |  |  |
| * Have we examined **social, cultural and policy factors** and their influence on the prospective success of the project? * Do all further steps in the project process reflect that knowledge? |  |  |  |
| Stakeholder/project partner | * Who needs to be addressed at the project partner and stakeholder level? Who are the specific stakeholders or potential project partners for this topic? (see Tool 6 *(Checklist: Identifying stakeholders for cross-border collaboration))* |  |  |  |
| * Have all stakeholders (including project partners and the target group) been **involved in designing the project objectives?** |  |  |  |
| Target group | * Do we know our target group well? (relevant demographic features, priority needs, wishes and social norms) * Essentially all patients with a medical condition in need of treatment and diagnostic services in the border regions |  |  |  |
| * Has the size of the target group been estimated (number of subjects)? |  |  |  |
| * Is it clear how the target group can be reached? |  |  |  |
| Organisational and legal issues | * Are the effectiveness of the planned intervention/the project objectives proven? |  |  |  |
| * Is there a clear picture of the overall process that needs to be implemented? |  |  |  |
| Identifying and addressing **legal issues** in advance, mostly related to the workforce, financing and reimbursement, cost-sharing etc.   * What legislation applies at the regional, national or EU level? * Are there any legal regulations that need to be changed to enable activities at the project level for the intended treatment and diagnostic services across the border? * Establish reliable and strong agreements among project partners and stakeholders |  |  |  |
| * Is a reorganisation of the partner facilities (structural and strategic) necessary to foster better cross-border services for patients? |  |  |  |
| * **ICT/telemedicine** for sharing patient information between different regional healthcare providers and ensuring a smooth treatment chain |  |  |  |
| * Gaining political support (at the regional, national and EU level) |  |  |  |
| Culture and trust are key issues for cross-border collaboration projects, especially when it comes to medical and care services for patients   * How will we ensure that these issues are reflected properly in the project partner development process and, at a later stage, in the process of providing services to patients? |  |  |  |
| Financing | * National funding and/or EU funding possibilities (provider perspective) |  |  |  |
| * Health insurance funds reimburse medical costs (patient perspective) |  |  |  |

Source: GOE FP

**LEGAL NOTICE**

This document was produced under the Health Programme (2014-2020) in the frame of a specific contract with the Consumers, Health, Agriculture and Food Executive Agency (Chafea) acting under the mandate of the European Commission. The content of this document represents the views of the contractor and is its sole responsibility; it can in no way be taken to reflect the views of the European Commission and/or Chafea or any other body of the European Union. The European Commission and/or Chafea do not guarantee the accuracy of the data included in this document, nor do they accept responsibility for any use made by third parties thereof.

Description: \\10.1.0.28\public\Organisation\Standards\Logos_2012\Forschung_Logo.eps****



Written by Gesundheit Österreich  
Forschungs und Planungs GmbH

March 2018